Aldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Above 50-Day Moving Average – Should You Sell?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $6.01 and traded as high as $6.81. Aldeyra Therapeutics shares last traded at $6.68, with a volume of 797,432 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, March 3rd.

Aldeyra Therapeutics Trading Down 0.6 %

The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The company’s fifty day moving average price is $6.03 and its 200 day moving average price is $5.51.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). As a group, equities analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current year.

Institutional Trading of Aldeyra Therapeutics

Several large investors have recently bought and sold shares of ALDX. Intech Investment Management LLC bought a new position in shares of Aldeyra Therapeutics in the third quarter worth about $79,000. BNP Paribas Financial Markets increased its holdings in Aldeyra Therapeutics by 253.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 10,201 shares in the last quarter. Captrust Financial Advisors raised its position in Aldeyra Therapeutics by 89.3% in the third quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 9,087 shares during the last quarter. PDT Partners LLC acquired a new stake in shares of Aldeyra Therapeutics during the third quarter valued at about $169,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Aldeyra Therapeutics during the third quarter valued at about $62,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.